The Efficacy of Fibroblast Growth Factor for the Treatment of Chronic Vocal Fold Scarring: From Animal Model to Clinical Application
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objectives. This study assessed the regenerative efficacy of basic fibroblast growth factor (FGF) in a rabbit model of chronic vocal fold scarring and then confirmed its utility and safety in a prospective trial of patients with this condition. Methods. FGF was injected three times, at 1-week intervals, into a chronic vocal fold scar created in a rabbit model. After 1 month, mRNA level of procollagen I, hyaluronic acid synthetase 2 (HAS 2), and matrix metalloproteinase 2 (MMP 2) were analyzed by real-time polymerase chain reaction. The relative densities of hyaluronic acid (HA) and collagen were examined 3 months post-injection. From April 2012 to September 2014, a prospective clinical trial was conducted at a tertiary hospital in Korea. FGF was injected into the mild vocal fold scar of 17 consecutive patients with a small glottic gap. The patients underwent perceptual, stroboscopic, acoustic aerodynamic test, and Voice Handicap Index (VHI) survey prior to and 3, 6, and 12 months after FGF injection. Results. FGF injection of the vocal fold scar decreased the density of collagen and increased mRNA level of HAS 2 and MMP 2 expression significantly compared to the control group injected with phosphate buffered solution in a rabbit model (P<0.05). In the clinical trial, significant improvements in the majority of the subjective and objective voice parameters were registered 3 months after FGF injection and were maintained at 12 months. Complications associated with the FGF injections, such as granuloma, were not observed during the follow-up period. Conclusion. Based on the animal model and the prospective clinical trial, vocal fold injections of FGF in patients with mild chronic vocal fold scarring can significantly improve voice quality for as long as 1 year and without side effects. Our results recommend the use of FGF vocal fold injection as an alternative treatment modality for mild chronic vocal fold scarring.
Abstract
Objectives. This study assessed the regenerative efficacy of basic fibroblast growth factor (FGF) in a rabbit model of chronic vocal fold scarring and then confirmed its utility and safety in a prospective trial of patients with this condition. Methods. FGF was injected three times, at 1-week intervals, into a chronic vocal fold scar created in a rabbit model. After 1 month, mRNA level of procollagen I, hyaluronic acid synthetase 2 (HAS 2), and matrix metalloproteinase 2 (MMP 2) were analyzed by real-time polymerase chain reaction. The relative densities of hyaluronic acid (HA) and collagen were examined 3 months post-injection. From April 2012 to September 2014, a prospective clinical trial was conducted at a tertiary hospital in Korea. FGF was injected into the mild vocal fold scar of 17 consecutive patients with a small glottic gap. The patients underwent perceptual, stroboscopic, acoustic aerodynamic test, and Voice Handicap Index (VHI) survey prior to and 3, 6, and 12 months after FGF injection. Results. FGF injection of the vocal fold scar decreased the density of collagen and increased mRNA level of HAS 2 and MMP 2 expression significantly compared to the control group injected with phosphate buffered solution in a rabbit model (P<0.05). In the clinical trial, significant improvements in the majority of the subjective and objective voice parameters were registered 3 months after FGF injection and were maintained at 12 months. Complications associated with the FGF injections, such as granuloma, were not observed during the follow-up period. Conclusion. Based on the animal model and the prospective clinical trial, vocal fold injections of FGF in patients with mild chronic vocal fold scarring can significantly improve voice quality for as long as 1 year and without side effects. Our results recommend the use of FGF vocal fold injection as an alternative treatment modality for mild chronic vocal fold scarring.
참고문헌 (22)
- Hirano S., "Current treatment of vocal fold scarring", Curr Opin Otolaryngol Head Neck Surg, 13(3), pp.143~147 (2005)
- Suehiro A, "Treatment of acute vocal fold scar with local injection of basic fibroblast growth factor: a canine study", Acta Otolaryngol, 130(7), pp.844~850 (2010)
- Rousseau B, "Characterization of chronic vocal fold scarring in a rabbit model", J Voice, 18(1), pp.116~124 (2004)
- Lim JY, "Regulation of wound healing by granulocyte-macrophage colony-stimulating factor after vocal fold injury", PLoS One, 8(1), pp.e54256~ (2013)
- Lee SW, "Augmentation of vocal fold using a fat block implant following cordotomy through a minithyrotomy approach in a rabbit model", J Voice, 26(4), pp.521~525 (2012)
- Hirano M., "Clinical examination of voice" (1981), Springer-Verlag
- 윤영선, "한국어판 음성장애지수(Voice Handicap Index, VHI)의 타당도 및 VHI-10의 임상적 유용성", Communication Sciences and Disorders, 13(2), pp.216~241 (2008), 한국언어청각임상학회
- 이승원, "Comparative Analysis of Efficiency of Injection Laryngoplasty Technique for with or without Neck Treatment Patients: A Transcartilaginous Approach Versus the Cricothyroid Approach", Clinical and Experimental Otorhinolaryngology, 3(1), pp.37~41 (2010), 대한이비인후과학회
- 윤경철, "Prevalence of Eye Diseases in South Korea: Data from the Korea National Health and Nutrition Examination Survey 2008-2009", Korean Journal of Ophthalmology, 25(6), pp.421~433 (2011), 대한안과학회
- Hirano S, "Histologic characterization of human scarred vocal folds", J Voice, 23(4), pp.399~407 (2009)
- Dailey SH, "Surgical management of sulcus vocalis and vocal fold scarring", Otolaryngol Clin North Am, 39(1), pp.23~42 (2006)
- Kanemaru S, "Regeneration of the vocal fold using autologous mesenchymal stem cells", Ann Otol Rhinol Laryngol, 112(11), pp.915~920 (2003)
- Hirano S, "Roles of hepatocyte growth factor and transforming growth factor beta1 in production of extracellular matrix by canine vocal fold fibroblasts", Laryngoscope, 113(1), pp.144~148 (2003)
- Hirano S, "Effect of growth factors on hyaluronan production by canine vocal fold fibroblasts", Ann Otol Rhinol Laryngol, 112(7), pp.617~624 (2003)
- Hirano S, "Prevention of vocal fold scarring by topical injection of hepatocyte growth factor in a rabbit model", Laryngoscope, 114(3), pp.548~556 (2004)
- Hirano S, "Growth factor therapy for vocal fold scarring in a canine model", Ann Otol Rhinol Laryngol, 113(10), pp.777~785 (2004)
- Ohno T, "Drug delivery system of hepatocyte growth factor for the treatment of vocal fold scarring in a canine model", Ann Otol Rhinol Laryngol, 116(10), pp.762~769 (2007)
- Hirano S, "Regenerative phonosurgical treatments for vocal fold scar and sulcus with basic fibroblast growth factor", Laryngoscope, 123(11), pp.2749~2755 (2013)
- Hong HH, "Cytokine regulation of gingival fibroblast lysyl oxidase, collagen, and elastin", J Periodontol, 73(2), pp.145~152 (2002)
- Heldin P, "Effect of growth factors on hyaluronan synthesis in cultured human fibroblasts", Biochem J, 258(3), pp.919~922 (1989)
- Kanazawa T, "Single injection of basic fibroblast growth factor to treat severe vocal fold lesions and vocal fold paralysis", Laryngoscope, 125(1), pp.E338~E344 (2015)
- Tateya T, "Immuno-scanning electron microscopy of collagen types I and III in human vocal fold lamina propria", Ann Otol Rhinol Laryngol, 116(2), pp.156~159 (2007)